Abstract: FR-PO1131
Kidney Donors and Long-Term Risk of CKD with Type 2 Diabetes and Obesity: Global Cohort Study Using Real-World Data
Session Information
- Transplantation: Clinical - Transplant Access, Recipient Evaluation, Living Donors, Pregnancy, and More
October 23, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Transplantation
- 2002 Transplantation: Clinical
Authors
- Kaur, Gurwant, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
- Raza, Muhammad, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
- Tahir, Maria, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
- Siddiqi, Mahwash, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
- Ghahramani, Nasrollah, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
Group or Team Name
- Penn State Nephrology
Background
Diabetes Mellitus type 2 (DM) and obesity are known risk factors for chronic kidney disease (CKD). We aimed to assess the incidence of CKD among the kidney donors (KD) a. with and without DM and Obesity class I b. with DM and without obesity class I c. with obesity class 1 and without DM.
Methods
Using the TriNetX Research Network, 39 healthcare organizations (HCO) we identified patients, cohort 1 (n 366), aged 18–99 years with documented history of a KD, DM and obesity class I (BMI 30.0–34.9 kg/m2). Cohort 2 (n = 57804, 92 HCO) identified KD without DM and obesity class I. Cohort 3 (n = 4911, 72 HCO) identified KD with DM and without obesity class 1. Cohort 4 (n = 1197, 40 HCO) identified KD with obesity class 1 and without DM. Outcomes were evaluated from one day post-index event through the available follow-up period. The primary outcome was incidence of CKD III-V. Kaplan-Meier survival curves, survival probability (SP), hazard ratios (HR), and risk ratios (RR) were calculated.
Results
KD with DM and obesity class I (cohort 1) had incidence of CKD III: 33.80 % vs. 3.41% (RR 9.8; P <0.0001; SP 22.75% vs. 80.64%; HR 13.5), risk of CKD IV: 11.62% vs. 0.75% (RR 15.44; P <0.0001; SP 79.3% vs. 96.68%; HR 16.0) and risk of CKD V 8.09% vs. 0.82% (RR 9.8; P <0.0001; SP 89.13% vs. 97.36%; HR 9.3) compared to KD without DM and obesity class I (cohort 2).
KD with DM without obesity class I (cohort 3) had risk of CKD III: 30.6% vs. 10.41% (RR 2.94; P <0.0001; SP 38.02% vs. 82.03%; HR 2.81), risk of CKD IV: 15.57% vs. 1.58% (RR 9.80; P <0.0001; SP 62.10% vs. 96.815%; HR 8.23) as compared to KD with obesity class 1 and without DM (cohort 4). Sample size was too small to calculate the risk of CKD V among the cohorts 3 & 4.
Conclusion
In this large, multicenter real-world cohort, the presence of both DM and obesity class 1 were associated with highest risk of CKD among the KDs. Risk of CKD was higher with presence of DM than obesity class I among the KD. These findings underscore the need for long-term nephrology follow-up and assess the risk of CKD progression for such patients.